BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including Orladeyo (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
BioCryst Pharmaceuticals announced that the company will present four abstracts on oral, once-daily Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The meeting will take place in Boston from October 24-28, 2024.
Poster Presentations
- Adherence And Persistence Among Hereditary Angioedema Patients Treated With Berotralstat, Lanadelumab, And Subcutaneous Plasma-Derived C1-Inhibitor; ePoster #R072; 2:30-2:45pm Eastern Time (ET), Friday 25 October 2024; Monitor #19, Hall A
- Sustained Real-World Attack Reductions Following Berotralstat Initiation Among Patients with Hereditary Angioedema with C1-Inhibitor Deficiency; ePoster #R092; 3:30-3:45pm ET, Friday 25 October 25; Monitor #20, Hall A
- Sustained Real-World Attack Reductions Following Berotralstat Initiation Among Patients with Hereditary Angioedema without C1-Inhibitor Deficiency; ePoster #R093; 3:45-4:00 pm ET, Friday 25 October; Monitor #20, Hall A
- Long-Term Prophylactic Treatment Preferences of Patients With Hereditary Angioedema; ePoster #R081; 4:45-5:00pm ET, Friday 25 October; Monitor #19, Hall A
(Source: BioCryst)